A Combination of a Dopamine Receptor 2 Agonist and a Kappa Opioid Receptor Antagonist Synergistically Reduces Weight in Diet-Induced Obese Rodents
Nutrients · 2024
DOI: 10.3390/nu16030424 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2024. Verfasst von Beatriz Cicuéndez und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain. Hauptthemen laut MEDLINE: Narcotic Antagonists, Receptors, Opioid, kappa, Biphenyl Compounds, Sulfonamides. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: La Caixa Foundation, Instituto de Salud Carlos III-Sara Borrell, EASO/Novo Nordisk.
Abstract (Originalsprache)
As the global obesity rate increases, so does the urgency to find effective anti-obesity drugs. In the search for therapeutic targets, central nervous system (CNS) mechanisms engaged in the regulation of energy expenditure and food intake, such as the opioid and dopamine systems, are crucial. In this study, we examined the effect on body weight of two drugs: bromocriptine (BC), a D2R receptor agonist, and PF-04455242, a selective κ opioid receptor (KOR) antagonist. Using diet-induced obese (DIO) rats, we aimed to ascertain whether the administration of BC and PF-04455242, independently or in combination, could enhance body weight loss. Furthermore, the present work demonstrates that the peripheral coadministration of BC and PF-04455242 enhances the reduction of weight in DIO rats and leads to a decrease in adiposity in a food-intake-independent manner. These effects were based on heightened energy expenditure, particularly through the activation of brown adipose tissue (BAT) thermogenesis. Overall, our findings indicate that the combination of BC and PF-04455242 effectively induces body weight loss through increased energy expenditure by increasing thermogenic activity and highlight the importance of the combined use of drugs to combat obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
ORCID-Profile: Beatriz Cicuéndez, Javier Pérez-García, Cintia Folgueira
Förderung
- La Caixa Foundation
- Instituto de Salud Carlos III-Sara Borrell
- EASO/Novo Nordisk
- EFSD/Lilly
- Society for Endocrinology
- FSEEN
- Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence
- “la Caixa” Foundation
Zitieren
APA
Cicuéndez, B., Pérez-García, J., & Folgueira, C. (2024). A Combination of a Dopamine Receptor 2 Agonist and a Kappa Opioid Receptor Antagonist Synergistically Reduces Weight in Diet-Induced Obese Rodents. Nutrients. https://doi.org/10.3390/nu16030424
Vancouver
Cicuéndez B, Pérez-García J, Folgueira C. A Combination of a Dopamine Receptor 2 Agonist and a Kappa Opioid Receptor Antagonist Synergistically Reduces Weight in Diet-Induced Obese Rodents. Nutrients. 2024. doi:10.3390/nu16030424
BibTeX
@article{Cicundez2024,
author = {Cicuéndez, Beatriz and Pérez-García, Javier and Folgueira, Cintia},
title = {A Combination of a Dopamine Receptor 2 Agonist and a Kappa Opioid Receptor Antagonist Synergistically Reduces Weight in Diet-Induced Obese Rodents},
journal = {Nutrients},
year = {2024},
doi = {10.3390/nu16030424}
}
EUVIMED